168 related articles for article (PubMed ID: 11052227)
1. PET studies and motor complications in Parkinson's disease.
Brooks DJ
Trends Neurosci; 2000 Oct; 23(10 Suppl):S101-8. PubMed ID: 11052227
[TBL] [Abstract][Full Text] [Related]
2. Striatal D2 dopamine receptor status in Parkinson's disease: an [18F]dopa and [11C]raclopride PET study.
Dentresangle C; Veyre L; Le Bars D; Pierre C; Lavenne F; Pollak P; Guerin J; Froment JC; Brousolle E
Mov Disord; 1999 Nov; 14(6):1025-30. PubMed ID: 10584682
[No Abstract] [Full Text] [Related]
3. Alterations in opioid receptor binding in Parkinson's disease patients with levodopa-induced dyskinesias.
Piccini P; Weeks RA; Brooks DJ
Ann Neurol; 1997 Nov; 42(5):720-6. PubMed ID: 9392571
[TBL] [Abstract][Full Text] [Related]
4. Pathophysiology of the basal ganglia in Parkinson's disease.
Obeso JA; Rodríguez-Oroz MC; Rodríguez M; Lanciego JL; Artieda J; Gonzalo N; Olanow CW
Trends Neurosci; 2000 Oct; 23(10 Suppl):S8-19. PubMed ID: 11052215
[TBL] [Abstract][Full Text] [Related]
5. Continuous dopamine-receptor stimulation in early Parkinson's disease.
Olanow W; Schapira AH; Rascol O
Trends Neurosci; 2000 Oct; 23(10 Suppl):S117-26. PubMed ID: 11052229
[TBL] [Abstract][Full Text] [Related]
6. Complementary positron emission tomographic studies of the striatal dopaminergic system in Parkinson's disease.
Antonini A; Vontobel P; Psylla M; Günther I; Maguire PR; Missimer J; Leenders KL
Arch Neurol; 1995 Dec; 52(12):1183-90. PubMed ID: 7492293
[TBL] [Abstract][Full Text] [Related]
7. Opioids and motor complications in Parkinson's disease.
Samadi P; Bédard PJ; Rouillard C
Trends Pharmacol Sci; 2006 Oct; 27(10):512-7. PubMed ID: 16908075
[TBL] [Abstract][Full Text] [Related]
8. Levodopa-induced changes in synaptic dopamine levels increase with progression of Parkinson's disease: implications for dyskinesias.
de la Fuente-Fernández R; Sossi V; Huang Z; Furtado S; Lu JQ; Calne DB; Ruth TJ; Stoessl AJ
Brain; 2004 Dec; 127(Pt 12):2747-54. PubMed ID: 15329355
[TBL] [Abstract][Full Text] [Related]
9. Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study.
Whone AL; Watts RL; Stoessl AJ; Davis M; Reske S; Nahmias C; Lang AE; Rascol O; Ribeiro MJ; Remy P; Poewe WH; Hauser RA; Brooks DJ;
Ann Neurol; 2003 Jul; 54(1):93-101. PubMed ID: 12838524
[TBL] [Abstract][Full Text] [Related]
10. Continuous dopamine-receptor stimulation in advanced Parkinson's disease.
Nutt JG; Obeso JA; Stocchi F
Trends Neurosci; 2000 Oct; 23(10 Suppl):S109-15. PubMed ID: 11052228
[TBL] [Abstract][Full Text] [Related]
11. Brain α7 nicotinic acetylcholine receptors in MPTP-lesioned monkeys and parkinsonian patients.
Morissette M; Morin N; Grégoire L; Rajput A; Rajput AH; Di Paolo T
Biochem Pharmacol; 2016 Jun; 109():62-69. PubMed ID: 27038656
[TBL] [Abstract][Full Text] [Related]
12. Ropinirole versus L-DOPA effects on striatal opioid peptide precursors in a rodent model of Parkinson's disease: implications for dyskinesia.
Ravenscroft P; Chalon S; Brotchie JM; Crossman AR
Exp Neurol; 2004 Jan; 185(1):36-46. PubMed ID: 14697317
[TBL] [Abstract][Full Text] [Related]
13. Molecular mechanisms of L-DOPA-induced dyskinesia.
Jenner P
Nat Rev Neurosci; 2008 Sep; 9(9):665-77. PubMed ID: 18714325
[TBL] [Abstract][Full Text] [Related]
14. Levodopa-induced changes in synaptic dopamine in patients with Parkinson's disease as measured by [11C]raclopride displacement and PET.
Tedroff J; Pedersen M; Aquilonius SM; Hartvig P; Jacobsson G; Långström B
Neurology; 1996 May; 46(5):1430-6. PubMed ID: 8628494
[TBL] [Abstract][Full Text] [Related]
15. Neuroimaging of dyskinesia.
Brooks DJ; Piccini P; Turjanski N; Samuel M
Ann Neurol; 2000 Apr; 47(4 Suppl 1):S154-8; discussion S158-9. PubMed ID: 10762143
[TBL] [Abstract][Full Text] [Related]
16. Age-related differences in levodopa dynamics in Parkinson's: implications for motor complications.
Sossi V; de la Fuente-Fernández R; Schulzer M; Adams J; Stoessl J
Brain; 2006 Apr; 129(Pt 4):1050-8. PubMed ID: 16476675
[TBL] [Abstract][Full Text] [Related]
17. A comparison of the progression of early Parkinson's disease in patients started on ropinirole or L-dopa: an 18F-dopa PET study.
Rakshi JS; Pavese N; Uema T; Ito K; Morrish PK; Bailey DL; Brooks DJ
J Neural Transm (Vienna); 2002 Dec; 109(12):1433-43. PubMed ID: 12486484
[TBL] [Abstract][Full Text] [Related]
18. Reproducibility and effect of levodopa on dopamine transporter function measurements: a [18F]CFT PET study.
Nurmi E; Bergman J; Eskola O; Solin O; Hinkka SM; Sonninen P; Rinne JO
J Cereb Blood Flow Metab; 2000 Nov; 20(11):1604-9. PubMed ID: 11083235
[TBL] [Abstract][Full Text] [Related]
19. Levodopa pharmacokinetic-pharmacodynamic modeling and 6-[18F]levodopa positron emission tomography in patients with Parkinson's disease.
Dietz M; Harder S; Graff J; Künig G; Vontobel P; Leenders KL; Baas H
Clin Pharmacol Ther; 2001 Jul; 70(1):33-41. PubMed ID: 11452242
[TBL] [Abstract][Full Text] [Related]
20. Serotonergic mechanisms responsible for levodopa-induced dyskinesias in Parkinson's disease patients.
Politis M; Wu K; Loane C; Brooks DJ; Kiferle L; Turkheimer FE; Bain P; Molloy S; Piccini P
J Clin Invest; 2014 Mar; 124(3):1340-9. PubMed ID: 24531549
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
